Novavax, Inc.

NVAX

US6700024010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:45:38 2025-07-15 pm EDT			5-day change	1st Jan Change
6.775 ^USD	-2.80%		-3.76%	-15.73%

Jun. 13	Moderna falls on doubts over new CDC panel's backing of RSV vaccine	RE
Jun. 12	Novavax: positive results for Covid/flu vaccine

Top MIdday Gainers

Published on 05/10/2024 at 13:44, updated on 05/10/2024 at 13:45

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novavax, Inc.

Moderna falls on doubts over new CDC panel's backing of RSV vaccine	Jun. 13	RE
Novavax: positive results for Covid/flu vaccine	Jun. 12
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents	Jun. 12	RE
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents	Jun. 11	RE
Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02:00 PM	Jun. 11
Global markets live: Tesla, Nvidia, Boeing, Mistral, Nintendo…	Jun. 11
Sector Update: Health Care Stocks Higher Pre-Bell Wednesday	Jun. 11	MT
Novavax's COVID-flu combo vaccine shows strong immune response in trial	Jun. 11	RE
Novavax's COVID-flu combo vaccine shows strong immune response in trial	Jun. 11	RE
Novavax's Covid-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of A Phase 3 Trial	Jun. 11	CI
Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study	Jun. 11	MT
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study	Jun. 11	RE
Novavax's Combo & Flu Vaccines Show Strong Immune Response, Tolerated Well in Phase 3 Trial	Jun. 11	RE
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	Jun. 10	RE
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	Jun. 10	RE
Novavax, Inc., Q1 2025 Earnings Call, May 08, 2025	Jun. 06
US CDC keeps COVID vaccine option for healthy children	May. 30	RE
US CDC keeps COVID vaccine option for healthy children	May. 30	RE
Novavax Inc - Eliminates COO Position, Terminates John Trizzino - SEC Filing	May. 27	RE
Novavax, Inc. Announces Termination of John Trizzino as Chief Operating Officer, Effective as of June 20, 2025	May. 27	CI
CDC Removes Healthy Children, Pregnant Women From COVID Vaccine Schedule	May. 27	MT
Moderna files for review of updated COVID vaccine	May. 23	RE
Moderna files for review of updated COVID vaccine	May. 23	RE
COVID shots should target newer strains of JN.1 variant, US FDA advisers say	May. 22	RE
COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say	May. 22	RE

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Employees

952

Sector

Biotechnology & Medical Research

Calendar

Aug. 05 - Q2 2025 Earnings Release (Projected)

More about the company